Phase Ib/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma

Journal article

Peer reviewed

D. Miller, D.S. Miller, E. Cheung, M. Huang, M. Schlumbrecht, A. Garcia, M. Loch, A. Jernigan, Z. Li, M. Chen, …

Annals of oncology, Vol.30, p.v422

2019-10

Metrics

3 Record Views

Title: Phase Ib/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
Creators: D. Miller - The University of Texas Southwestern Medical Center
D.S. Miller - The University of Texas Southwestern Medical Center
E. Cheung - Clinical Research Institute
M. Huang - University of Miami
M. Schlumbrecht - University of Miami
A. Garcia - Louisiana State University
M. Loch - Louisiana State University
A. Jernigan - Louisiana State University
Z. Li - Advenchen Laboratories, Moorpark, CA, USA
M. Chen - Advenchen Laboratories, Moorpark, CA, USA
J. Chen - Advenchen Laboratories, Moorpark, CA, USA
Publication Details: Annals of oncology, Vol.30, p.v422
Academic Unit: Miller School of Medicine; UMMG Dept of Obstetrics & Gynecology
Language: English
Resource Type: Journal article
Record Identifier: 991031713415802976